Product News and Recalls

Pradaxa Linked with Increased Risk of Gastrointestinal Bleeding

A new study shows the use of the anti-coagulant known as Pradaxa is associated with a significant increase in the risk of gastrointestinal bleeding. The increased risk is compared to traditional or standard treatment with drugs such as enoxaparin, warfarin, antiplatelet therapy, or no therapy (placebo).

The study analyzed 17 randomized controlled trails and found an increased risk for gastrointestinal bleeding for patients taking newer anti-coagulants versus the more traditional treatments. Although there was a significant increased risk associated with Pradaxa, other newer anti-coagulants were not associated with an increased the risk of gastrointestinal bleeding.

The researchers found the results to be alarming, considering the widespread use of Pradaxa. They called for clear and precise guidelines for use of these drugs and how to manage any internal bleeding problems.
Pradaxa has been linked to hundreds of deaths since it entered the market and its users have experienced internal bleeding including bleeding in the brain, intestines, and kidneys. Pradaxa use has also been linked to an increased risk of heart attack. As a result of all this, personal injury lawsuits are being filed on behalf of injured patients.

If you or a loved one experienced any type of internal bleeding while taking Pradaxa, you may be eligible to recover damages. Please contact Lopez McHugh, LLP for a free evaluation.